LabCorp Reports Q2 2026 Earnings with Strong Revenue and Margin Growth
LabCorp (NYSE: LH) posted strong financial results for the second quarter of 2026, reporting enterprise revenue of $3.7 billion, a year-over-year increase of 5.8%. This growth was driven by both organic expansion at 4.2% and contributions from recent acquisitions. The company's adjusted operating margin expanded to 15.8%, up 70 basis points compared to the prior year, reflecting improved operational efficiency. Adjusted earnings per share (EPS) rose 14.9% to $4.99 due to strong performance across business segments and disciplined cost management. The Diagnostics segment saw revenue of $2.9 billion with a 5.5% increase driven by volume growth and favorable pricing, while the Biopharma Laboratory Services (BLS) segment grew at 6.5%, led by Central Laboratories. LabCorp also provided updated full-year guidance for enterprise revenue between 5.4% to 6.3%. The company maintained its free cash flow forecast of $1.24 billion to $1.36 billion and announced a share repurchase authorization increase, signaling confidence in capital deployment.
Tickers: $LH